Goldman Sachs Raises VKTX Target Price to $38 Amid Analyst's 47.1% Success Rate

Goldman Sachs analyst Richard Law CFA has maintained a 'hold' rating on Viking Therapeutics (VKTX.US), adjusting their target price from $30 to $38.

The adjustment is based on data from TipRanks, which provides analysis of financial analysts' recommendations. The analyst's success rate over the past year stands at 47.1%, with a total average return of 8.0%.

TipRanks calculates success rates and returns by tracking virtual portfolios established on preliminary ratings. The ranking system assigns up to five stars, indicating better performance based on total success rate and average return.